COX-2 Expression and Chemotherapy Resistance in Ovarian Cancer
Author Information
Author(s): Gabriella Ferrandina, Franco O. Ranelletti, Enrica Martinelli, Amelia Paglia, Gian Franco Zannoni, Giovanni Scambia
Primary Institution: Catholic University, Rome, Italy
Hypothesis
Is there an association between COX-2 expression and response to different chemotherapy regimens in advanced ovarian cancer?
Conclusion
The study suggests that COX-2 expression may influence chemotherapy response differently depending on the treatment regimen.
Supporting Evidence
- COX-2 positivity was found in 71.4% of not responding cases compared to 36.1% of responding cases.
- In platinum-based chemotherapy, 84.6% of unresponsive patients were COX-2 positive.
- The study suggests a potential difference in COX-2's influence on chemotherapy response based on treatment type.
Takeaway
This study looks at how a protein called COX-2 might affect how well ovarian cancer patients respond to different types of chemotherapy.
Methodology
A retrospective study analyzing COX-2 expression in tumor samples from 68 ovarian cancer patients and their response to chemotherapy.
Limitations
The relatively small sample size limits the power of the analysis.
Participant Demographics
Median age was 57 years, with 73.5% at stage IIIC and 26.5% at stage IV.
Statistical Information
P-Value
0.0072
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website